Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-73
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AC-73 is a first-in-class, specific, orally active small-molecule inhibitor of cluster of differentiation 147 (CD147), also known as basigin or EMMPRIN. It functions by specifically disrupting CD147 dimerization, which is implicated in tumor metastasis and progression. Preclinical studies have shown that AC-73 can inhibit hepatocellular carcinoma metastasis by targeting CD147-mediated signaling pathways[1][2]. The compound represents a novel approach for anti-cancer therapy, particularly in the context of metastatic disease.
- Other names
- AC73AC-73AC 73
02
Targets
BSG (Basigin)
Beyond the preview
Go deeper on AC-73.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AC-73.